Plasma kallikrein inhibitors

A compound of the formula:

• wherein
• is selected from
• X1 is CH or N;
• X2 is NR4 or CR4;
• X3 is N, NO, NRx or C═O;
• X4 is CH or N;
• Y is CR5R6 or SO2;
• Q is N or CH;
• G is N or CR7;
• J is N or CR7;
• L is N or CR7;
• M is N or CR7;
• R1 is selected from the group consisting of hydrogen, halo, cyano, Rx, ORx, heteroaryl and SO2Rx;
• R2 is hydrogen or halo;
• R3 is hydrogen, halo or ORx;
• R4 is hydrogen, Rx, ORx, (C═O)ORx, (C═O)NRxRy, C1-3 alkyl-ORx or NRxRy;
• R5 is hydrogen or C1-3 alkyl, which is optionally substituted with one to three substituents selected from deuterium, halo and hydroxy;
• R6 is hydrogen, deuterium or C1-3 alkyl;
• or R5 and R6 can be taken together with the carbon atom between them to form a C3-6 cycloalkyl group;
• each R7 is independently selected from the group consisting of halo, cyano, Rx, ORx, cyclopropyl, (C═O)NRxRy and NRxRy;
• or R5 and R7 can be taken together with the atoms between them to form a C3-6 cycloalkyl group;
• each R9 is independently selected from the group consisting of hydrogen, halo, hydroxy, cyano, triazolyl, cyclopropyl, (C═O)NRxRy, (C═O)Rx and C1-3 alkyl, wherein said triazolyl group is optionally substituted with Rx, said cyclopropyl group is optionally substituted with Rx or ORx, and said alkyl group is optionally substituted with one to four substituents selected from halo, hydroxy, heteroaryl, heterocyclyl, C3-6 cycloalkyl, C3-6 cycloalkyl(R10), ORx, (C═O)NRxRy and NRxRy;
• R10 is hydrogen, halo, hydroxy or C1-3 alkyl, wherein said alkyl is optionally substituted with one to four substituents selected from halo and hydroxy;
• R11 is hydrogen, halo, hydroxy or Rx;
• or R10 and R11 can be taken together with the atoms between them to form a C3-6 cycloalkyl group;
• each Rx is independently hydrogen or C1-6 alkyl, which is optionally substituted with one to four substituents selected from halo and hydroxy;
• each Ry is independently selected from the group consisting of hydrogen, C1-6 alkyl, C3-6 cycloalkyl, CH2—C3-6 cycloalkyl and heterocyclyl, wherein said alkyl is optionally substituted with one to four substituents selected from halo and hydroxy, said cycloalkyl is optionally substituted with one or two Rx or ORx and said heterocyclyl is optionally substituted with one or two R10;
• m is an integer from zero to two;
• n is an integer from zero to two;
• or a pharmaceutically acceptable salt thereof.